You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Severe eosinophilic asthma,NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients
aged 12 years and over (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
Trials).,Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),NUCALA is indicated as add-on treatment in adult patients (18 years and above) with
severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to
intranasal corticosteroids (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
2 Trials).,Relapsed or refractory EGPA,NUCALA is indicated as an add-on treatment for relapsing or refractory Eosinophilic
Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see
section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Severe eosinophilic asthma,NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients
aged 12 years and over (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
Trials).,Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),NUCALA is indicated as add-on treatment in adult patients (18 years and above) with
severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to
intranasal corticosteroids (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
2 Trials).,Relapsed or refractory EGPA,NUCALA is indicated as an add-on treatment for relapsing or refractory Eosinophilic
Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see
section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Severe eosinophilic asthma,NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients
aged 12 years and over (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
Trials).,Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),NUCALA is indicated as add-on treatment in adult patients (18 years and above) with
severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to
intranasal corticosteroids (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
2 Trials).,Relapsed or refractory EGPA,NUCALA is indicated as an add-on treatment for relapsing or refractory Eosinophilic
Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see
section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
